Substance P

Phase 1Small molecule

GSK

Substance P is one of 69 small molecule programs targeting Headache. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AngioedemaActive, not recruiting

MigraineActive, not recruiting

Type 1 DiabetesActive, not recruiting

AngioedemaPreclinical

Active, not recruiting

MigrainePreclinical

Active, not recruiting

Type 1 DiabetesPhase 1

Active, not recruiting

Competition

Competitive Landscape

384 competitors in Type 1 Diabetes

#DrugCompanyPhaseTrials

Symlin

AstraZeneca

Preclinical

4 2

Symlin

AstraZeneca

Preclinical

3 3

Aldomet

Neurocrine Biosciences

Preclinical

2 4

Pitocin

RRetrophin

Preclinical

1 5

Glargine

Eli Lilly

Preclinical

4 6

Cytoxan

BBaxter Healthcare Corporation

Preclinical

1 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Foradil

Viatris

Preclinical

1 9

Substance P

GSK

Phase 1

1 10

SGLT2 Inhibitor

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Migraine

NCT06959004

Clinical

Trials by Indication[1]

Migraine1 trial

Substance P-Induced Migraine Attacks Without Aura

Recruiting·DDanish Headache Center·N/A·NCT06959004·21 enrolled

Antibody1 trial

Reduction of IgE Antibody in Human Allergic Subjects

Completed·NNorthwestern University·Phase 1·NCT01280149·40 enrolled

ARB1 trial

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

Terminated·VVanderbilt University Medical Center·Phase 4·NCT03738878·4 enrolled

Type 1 Diabetes1 trial

Neuropeptide Therapy of Recent Onset Type 1 Diabetes

Unknown status·VVanilloid Genetics Inc.·Phase 1·NCT02820558·12 enrolled

Headache1 trial

Effects of Substance P on Headache Induction in Healthy Individuals

Not yet recruiting·DDanish Headache Center·N/A·NCT06632080·21 enrolled

2 more indications

Angioedema1 trial

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

Completed·VVanderbilt University·N/A·NCT01413542·44 enrolled

ART1 trial

Substance P Challenge in Healthy Participants

Completed· GSK logo

GSK·N/A·NCT04676763·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Substance P. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Substance P compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Substance P. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: GSK

Substance P

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Migraine1 trial

Antibody1 trial

ARB1 trial

Type 1 Diabetes1 trial

Headache1 trial

Angioedema1 trial

ART1 trial

References

Drug Info

Quick Facts

Related News